Myanmar BBurma B
The Hepatitis B - Myanmar Forum
Thank you, Maneki and Silverswimmer. Maneki, in the UK I don't think the two shots are usually done together as having a Hep B shot is not the commons (not surprisingly, at £130 or so a course!). We' ll not be in a 5-star lodging, just in the midst of the street, and will not plan to eat at the resort, but then dinner is no problem for Hep B. We already have Hep A, typhus, diphtheria and poliomyelitis footage from past travels.
Burma has a total of 51 million inhabitants. One recent statewide survey estimated that 3. 5 million will live with Hepatitis B and another 1.1. million will live with Haepatitis C. The Country faces several main challenges if it provides sufficient screening and care for himpatitis. Service for haematitis is severely understaffed.
There''s no government funding for the treatment of HCV. But there are few skilled Myanmaradiologists and there is no MRI in the city. Hepatic biopsy is not performed as a routine procedure and prenatal testing is not possible. There are better service providers in the residential market, but there are usually $5 to $10 for a one-on-one counsel.
At home, laboratory service supports the fundamental biochemical, haematological and serological aspects of virus wepatitis. The fast point-of-care test kit (US 50 cents - $2) and lever activity test (about $20 each) used to detect chronic inflammation are significant expenditures for the majority of the general public, whose monthly averages are less than $50 per year.
In the case of HC, the presence of medicines is a major obstacle to therapy. In Myanmar, only sofa buvir is currently enrolled, other medicines for inflammatory diseases are not enrolled. The majority of anti-viral treatments for haepatitis B are available in Myanmar and have been recorded. Even though the children's B vaccine program for HCV has been running for 10 years, wherever possible involving childbirth dose, there are still practical difficulties.
Furthermore, there are no ongoing domestic policy or immunisation schemes for high-risk groups, which include healthcare personnel, catch-up schemes for infants, immunisation for people infected with HIV and for people who live in orphans. While many NGOs offer a free screen test and some vaccinations, the cost limits the room for manoeuvre.
Others, such as Medical Action Myanmar (MAM), are continuing to investigate and may be providing vaccine. On our last visit to Myanmar, we participated in educational, research and collaboration activities to evaluate the current state of the disease in Myanmar and to prepare the ground for further programmes. With the Myanmar Liver Foundation (MLF), which has conducted over 100,000 immunizations to date, and the Medical Action Myanmar (MAM), an NGO with powerful HIV and antimalarial programmes, we discussed the needs and standing of HCV programmes.
Tightly, B is planning to free the effect of delivering vaccines outside the refrigeration cycle and match topical NGOs to provide efficient screening strategies and treatments for HC. Work with MLF and MLF to test and immunize high-risk groups: HIV infected, kids in orphans' homes, kids in MLF hospitals and healthcare professionals.
Our plans are to work with our partner communities to develop and promote education and resources for both governmental and non-governmental haepatologists, gastronomic enterologists and other related professionals, basic healthcare professionals, medical staff, nursing staff, and the general population. Also we will work for changes in the field of prophylaxis through screenings and inoculations.
Our commitment will be to ensure that the international fellowship and our stakeholders have easy and cost-effective quick-testing. In line with the goals of the WHOGAP 2011-2010 WHO World Vaccine Action Plan, we will work for the availability of less expensive immunization immunizations for vulnerable people. UNICEF's vaccine purchases are only 30 cent, but are currently not available without the cooperation of the Ministry of Health in Myanmar.
Treatments: In addition, we will support our regional partner in developing appropriate guidance for the management of HC and B HC. Exploring possibilities and facilitating accessibility to more accessible anti-viral therapies for HC and BHP, such as the Gilead regimen.
It is also our intention to research and promote cost effective laboratory testing together with our global partner companies and to impart technological capabilities and knowledge. It is our aim to promote research activity and to make available our resource and engineering knowledge in the conception, implementation and publishing of local surveys.